Read Research Alzheimer's More' title='Share this by email.' class='social email'>           

Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease

Blood-based biomarkers of pathophysiological brain amyloid β (Aβ) accumulation, particularly for preclinical target and large-scale interventions, are warranted to effectively enrich Alzheimer’s disease clinical trials and management. Read & Research Alzheimer’s More

Leave a Reply